This study evaluated whether there was an association between statin (a type of cholesterol-lowering medication) use and prostate cancer (PCa) mortality. This study found that stain use resulted in lower rates of PCa-specific mortality, in particular with the use of hydrophilic statins.

This study reviewed the association between nocturia and falls and fractures. Researchers suggested that nocturia is associated with a 1.2-fold increased risk of falls and a 1.3-fold increase in fractures.

This study investigated whether salt intake contributes to nocturia (excessive urination at night). Researchers suggested that salt intake is associated with nocturia in elderly men.

This study examined the levels of vitamin D in patients with prostate cancer (PC) to see if they were linked to patients’ chances of survival. The results showed that patients with higher levels of active vitamin D had a greater chance of survival.

This study reviewed the effect of diet on nocturia (waking up at night to urinate) severity. 

This study investigated the frequency, types, and predictive factors for nocturia (night-time urinating). Researchers suggested that nocturia is common in patients with urinary symptoms and causes significant bother.

This study evaluated if the benefit of adding abiraterone acetate (Zytiga) + prednisone (Deltasone) to androgen-deprivation therapy (ADT) in treating metastatic, castration-sensitive prostate cancer (mCSPC) would be maintained in patients treated with ADT alone. This study concluded that this treatment improved patients’ survival in these patients.

This study reviewed the management options for nocturia. They found that treating nocturia depends on the underlying cause. 

This study reviewed nocturia and its treatment.

This study investigated whether adding apalutamide (erleada) to androgen-deprivation therapy (ADT) would improve survival in patients with prostate cancer. The authors concluded that adding apalutamide to ADT improved outcomes for these patients.